Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group.

Fiche publication

Date publication

février 2026

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DESMOULINS Isabelle , Dr GANTZER Justine

Tous les auteurs :
Kalfala E, Meurgey A, Hénon C, Brahmi M, Toulmonde M, Boudou-Rouquette P, Bompas E, Penel N, Firmin N, Duffaud F, Desmoulins I, Ducoulombier A, Cancel M, Watson S, Khettab M, Darbas T, Kieffer A, Guillemet C, Gantzer J, Perrin C, Genevois AL, Orbach D, Chabaud S, Blay JY, Dufresne A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41719753

Résumé

Alveolar soft part sarcoma (ASPS) is an ultra-rare sarcoma with limited chemotherapy sensitivity affecting mostly young patients. Tyrosine kinase inhibitors (TKIs) and immunotherapy are therapeutic advances with promising results in this disease. The aim of this study was to describe the characteristics, management and survival of patients with ASPS in France.